Acadia Pharmaceuticals Inc (ACAD) is trading up at $20.31 (+0.59%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Analyst price targets on ACAD
Current price targets from 2 firms average $35, ranging from $33 to $37 — 72% above the current $20.3. Each is tracked to its date and scored the same way a member's call is.
- RBC Capital Markets $20.1 → $37 by Oct 2027 Oct 5, 2026 via Investing.com · RBC Capital Markets's track record
- H.C. Wainwright $20.5 → $33 by Sep 2027 Sep 28, 2026 via Investing.com · H.C. Wainwright's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Acadia Pharmaceuticals Inc revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $17.3M | $124.9M | $223.8M | $339.1M | $441.8M | $484.1M | $517.2M | $726.4M | $957.8M | $1.07B |
| Growth (year over year) | +28311.5% | +620.7% | +79.2% | +51.5% | +30.3% | +9.6% | +6.8% | +40.4% | +31.8% | +11.9% |
| Gross profit | $14.3M | $115.8M | $211.4M | $327.7M | $431.5M | $473.3M | $507.1M | $684.8M | $876.0M | $982.5M |
| Gross margin | 82.2% | 92.7% | 94.5% | 96.7% | 97.7% | 97.8% | 98.0% | 94.3% | 91.5% | 91.7% |
| Operating income | −$272.8M | −$292.4M | −$247.4M | −$246.5M | −$286.6M | −$170.4M | −$223.6M | −$73.4M | $230.8M | $104.8M |
| Operating margin | −1574.1% | −234.1% | −110.6% | −72.7% | −64.9% | −35.2% | −43.2% | −10.1% | 24.1% | 9.8% |
| Net income | −$271.4M | −$289.4M | −$245.2M | −$235.3M | −$281.6M | −$167.9M | −$216.0M | −$61.3M | $226.5M | $391.0M |
| Net margin | −1565.9% | −231.7% | −109.6% | −69.4% | −63.7% | −34.7% | −41.8% | −8.4% | 23.6% | 36.5% |
| EPS (diluted) | −$2.34 | −$2.36 | −$1.94 | −$1.60 | −$1.79 | −$1.05 | −$1.34 | −$0.37 | $1.36 | $2.30 |
| Balance sheet | ||||||||||
| Cash and equivalents | $163.6M | $69.4M | $134.8M | $189.7M | $326.0M | $147.4M | $114.8M | $188.7M | $319.6M | $177.7M |
| Total assets | $561.2M | $384.5M | $540.2M | $783.2M | $782.6M | $700.1M | $587.8M | $749.0M | $1.19B | $1.56B |
| Total liabilities | $42.7M | $49.2M | $61.1M | $84.0M | $155.6M | $159.2M | $187.4M | $317.2M | $455.0M | $336.8M |
| Shareholders' equity | $518.4M | $335.3M | $479.1M | $699.1M | $627.0M | $540.9M | $400.4M | $431.8M | $732.8M | $1.23B |
| Cash flow | ||||||||||
| Operating cash flow | −$208.4M | −$217.8M | −$167.5M | −$151.1M | −$136.2M | −$125.7M | −$114.0M | $16.7M | $157.7M | $109.8M |
| Capital expenditure | $1.51M | $812.0K | $2.10M | $1.13M | $7.59M | $1.12M | $0 | $50.0K | $523.0K | $4.69M |
| Free cash flow | −$209.9M | −$218.6M | −$169.6M | −$152.3M | −$143.8M | −$126.8M | −$114.0M | $16.7M | $157.2M | $105.1M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $250.4M | $259.6M | $244.3M | $264.6M | $278.6M | $284.0M | $268.1M | $308.0M |
| Growth (year over year) | +18.3% | +12.4% | +18.7% | +9.3% | +11.3% | +9.4% | +9.7% | +16.4% |
| Gross profit | $231.5M | $237.8M | $223.9M | $243.8M | $257.0M | $257.8M | $243.3M | $279.6M |
| Gross margin | 92.5% | 91.6% | 91.7% | 92.2% | 92.2% | 90.8% | 90.8% | 90.8% |
| Operating income | $31.6M | $153.5M | $19.3M | $32.4M | $35.8M | $17.4M | −$4.62M | $37.8M |
| Operating margin | 12.6% | 59.1% | 7.9% | 12.2% | 12.8% | 6.1% | −1.7% | 12.3% |
| Net income | $32.8M | $143.7M | $19.0M | $26.7M | $71.8M | $273.6M | $3.64M | $31.5M |
| Net margin | 13.1% | 55.4% | 7.8% | 10.1% | 25.8% | 96.3% | 1.4% | 10.2% |
| EPS (diluted) | $0.20 | $0.86 | $0.11 | $0.16 | $0.42 | $1.61 | $0.02 | $0.18 |
| Balance sheet | ||||||||
| Cash and equivalents | $155.1M | $319.6M | $217.7M | $253.6M | $258.0M | $177.7M | $282.2M | $385.0M |
| Total assets | $976.9M | $1.19B | $1.13B | $1.23B | $1.33B | $1.56B | $1.61B | $1.74B |
| Total liabilities | $399.7M | $455.0M | $367.1M | $403.2M | $413.5M | $336.8M | $357.2M | $436.3M |
| Shareholders' equity | $577.2M | $732.8M | $765.2M | $822.4M | $917.3M | $1.23B | $1.25B | $1.31B |
| Cash flow | ||||||||
| Operating cash flow | $63.2M | $40.4M | $20.3M | $64.0M | $74.3M | −$48.7M | $34.0M | $100.8M |
| Capital expenditure | $70.0K | $453.0K | $0 | $297.0K | $388.0K | $4.00M | $5.21M | $5.09M |
| Free cash flow | $63.2M | $39.9M | $20.3M | $63.7M | $73.9M | −$52.7M | $28.8M | $95.7M |
From Acadia Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Acadia Pharmaceuticals Inc
- Headquarters
- San Diego, California From SEC filings, Oct 2026
Recent News (4)
-
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insmed (INSM) Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), ACADIA Pharmaceuticals (ACAD) and Insmed (INSM) The Globe and Mail
-
RBC Capital reiterates Acadia Pharmaceuticals stock rating on patent developments
RBC Capital reiterates Acadia Pharmaceuticals stock rating on patent developments
-
Acadia Pharmaceuticals stock price target lowered to $33 by H.C. Wainwright
Acadia Pharmaceuticals stock price target lowered to $33 by H.C. Wainwright
-
Goldman Sachs reiterates Acadia Pharmaceuticals stock Sell rating after trial miss
Goldman Sachs reiterates Acadia Pharmaceuticals stock Sell rating after trial miss
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International